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A B S T R A C T
Background
Pain is a common feature of childhood and adolescence around the world, and for many young people, that pain is chronic. The World
Health Organization guidelines for pharmacological treatments for children’s persisting pain acknowledge that pain in children is a
major public health concern of high significance in most parts of the world. While in the past, pain was largely dismissed and was
frequently left untreated, views on children’s pain have changed over time, and relief of pain is now seen as important.
We designed a suite of seven reviews on chronic non-cancer pain and cancer pain (looking at antidepressants, antiepileptic drugs, non-
steroidal anti-inflammatory drugs, opioids, and paracetamol as priority areas) in order to review the evidence for children’s pain utilising
pharmacological interventions in children and adolescents.
As the leading cause of morbidity in children and adolescents in the world today, chronic disease (and its associated pain) is a major
health concern. Chronic pain (lasting three months or longer) can arise in the paediatric population in a variety of pathophysiological
classifications: nociceptive, neuropathic, idiopathic, visceral, nerve damage pain, chronic musculoskeletal pain, and chronic abdominal
pain, and other unknown reasons.
Paracetamol (acetaminophen) is one of the most widely used analgesics in both adults and children. The recommended dosage in the
UK, Europe, Australia, and the USA for children and adolescents is generally 10 to 15 mg/kg every four to six hours, with specific age
ranges from 60 mg (6 to 12 months old) up to 500 to 1000 mg (over 12 years old). Paracetamol is the only recommended analgesic
for children under 3 months of age. Paracetamol has been proven to be safe in appropriate and controlled dosages, however potential
adverse effects of paracetamol if overdosed or overused in children include liver and kidney failure.
Objectives
To assess the analgesic efficacy and adverse events of paracetamol (acetaminophen) used to treat chronic non-cancer pain in children
and adolescents aged between birth and 17 years, in any setting.
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Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL) via the Cochrane Register of Studies Online, MEDLINE
via Ovid, and Embase via Ovid from inception to 6 September 2016. We also searched the reference lists of retrieved studies and
reviews, and searched online clinical trial registries.
Selection criteria
Randomised controlled trials, with or without blinding, of any dose and any route, treating chronic non-cancer pain in children and
adolescents, comparing paracetamol with placebo or an active comparator.
Data collection and analysis
Two review authors independently assessed studies for eligibility. We planned to use dichotomous data to calculate risk ratio and
numbers needed to treat, using standard methods where data were available. We assessed GRADE (Grading of Recommendations
Assessment, Development and Evaluation) and planned to create a ’Summary of findings’ table.
Main results
No studies were eligible for inclusion in this review. We rated the quality of the evidence as very low. We downgraded the quality of
evidence by three levels due to the lack of data reported for any outcome.
Authors’ conclusions
There was no evidence from randomised controlled trials to support or refute the use of paracetamol (acetaminophen) to treat chronic
non-cancer pain in children and adolescents. We are unable to comment about efficacy or harm from the use of paracetamol to treat
chronic non-cancer pain in children and adolescents.
We know from adult randomised controlled trials that paracetamol, can be effective, in certain doses, and in certain pain conditions
(not always chronic).
This means that no conclusions could be made about efficacy or harm in the use of paracetamol (acetaminophen) to treat chronic non-
cancer pain in children and adolescents.
P L A I N L A N G U A G E S U M M A R Y
Paracetamol for chronic non-cancer pain in children and adolescents
Bottom line
There is no evidence from randomised controlled trials to support or refute the suggestion that paracetamol (acetaminophen) in any
dose will provide pain relief for chronic non-cancer pain in children or adolescents.
Background
Children can experience chronic or recurrent pain related to genetic conditions, nerve damage pain, chronic musculoskeletal pain, and
chronic abdominal pain, as well as for other unknown reasons. Chronic pain is pain that lasts three months or longer and is commonly
accompanied by changes in lifestyle, functional abilities, as well as by signs and symptoms of depression and anxiety.
Paracetamol (acetaminophen) is one of the most widely used painkillers in both adults and children. The recommended dosage in the
UK, Europe, Australia, and theUSA for children and adolescents is generally 10 to 15 mg/kg every four to six hours, with specific age
ranges from 60 mg (6 to 12 months old) up to 500 to 1000 mg (over 12 years old). Paracetamol is the only recommended painkiller
for children under 3 months of age. Paracetamol has been proven to be safe in appropriate and controlled dosages, however potential
side effects of paracetamol if overdosed or overused in children include liver and kidney failure.
Key results
In September 2016 we searched for clinical trials where paracetamol was used to treat chronic pain (potentially from either nerve pain,
musculoskeletal problems, menstrual cramps, or abdominal discomfort).
We found no studies that met the requirements for this review. Several studies tested paracetamol on adults with chronic pain, but
none included participants from birth to 17 years old.
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Quality of the evidence
We rated the quality of the evidence from studies using four levels: very low, low, moderate, or high. Very low quality evidence means
that we are very uncertain about the results. High quality evidence means that we are very confident in the results.
We rated the quality of evidence as very low, due to finding no evidence from randomised controlled trials to support or refute the
suggestion that paracetamol in any dose will reduce chronic non-cancer pain in children or adolescents.
B A C K G R O U N D
Pain is a common feature of childhood and adolescence around the
world, and formany youngpeople, that pain is chronic. TheWorld
Health Organization guidelines for pharmacological treatments
for persisting pain in children acknowledge that pain in children
is a major public health concern of high significance in most parts
of the world (WHO 2012). While in the past, pain was largely
dismissed and was frequently left untreated, views on children’s
pain have changed over time, and relief of pain is now seen as
important. Since the 1970s, studies comparing child and adult
pain management have revealed a variety of responses to pain,
fuelling the need for a more in-depth focus on paediatric pain
(Caes 2016).
Infants (zero to 12 months), children (1 to 9 years), and adoles-
cents (10 to 18 years), WHO 2012, account for 27% (1.9 billion)
of the world’s population (United Nations 2015); the proportion
of those aged 14 years and under ranges from12% (inHongKong)
to 50% (in Niger) (World Bank 2014). However, little is known
about the painmanagement needs of this population. For example,
in the Cochrane Library, approximately 12 reviews produced by
the Cochrane Pain, Palliative and Supportive Care Review Group
in the past 18 years have been specifically concerned with children
and adolescents, compared to over 100 reviews specific to adults.
Additional motivating factors for investigating children’s pain in-
clude the vast amount of unmanaged pain in the paediatric pop-
ulation and the development of new technologies and treatments.
We convened an international group of leaders in paediatric pain
to design a suite of seven reviews in chronic pain and cancer pain
(looking at antidepressants, antiepileptic drugs, non-steroidal anti-
inflammatory drugs, opioids, and paracetamol as priority areas) in
order to review the evidence under a programme grant for chil-
dren’s pain utilising pharmacological interventions in children and
adolescents (Appendix 1).
This review is based on a template for reviews of pharmacothera-
pies used to relieve pain in infants, children, and adolescents. The
aim is for all reviews to use the same methods, based on new cri-
teria for what constitutes reliable evidence (Appendix 2) (Moore
2010a; Moore 2012). This review focused on paracetamol (ac-
etaminophen) to treat chronic non-cancer pain.
Description of the condition
This review focused on chronic non-cancer pain experienced by
children and adolescents as a result of any type of chronic disease
that occurs throughout the global paediatric population. Chil-
dren’s level of pain can bemild, moderate, or severe, and painman-
agement is an essential element of patient management during all
care stages of chronic disease.
As the leading cause of morbidity in children and adolescents in
the world today, chronic disease (and its associated pain) is a major
health concern. Chronic pain can arise in the paediatric popula-
tion in a variety of pathophysiological classifications: nociceptive,
neuropathic, idiopathic, or visceral. Chronic pain is pain that lasts
three months or longer and is commonly accompanied by changes
in lifestyle, functional abilities, as well as by signs and symptoms
of depression and anxiety (Ripamonti 2008).
Whilst diagnostic and perioperative procedures performed to treat
chronic diseases are a known common cause of pain in these pa-
tients, this review did not cover perioperative pain or adverse ef-
fects of treatments such as mucositis.
Description of the intervention
Paracetamol (also known as acetaminophen) is one of the most
widely used analgesics around the world in both the adult and
paediatric populations. First marketed in the USA and UK in the
1950s, paracetamol is now recommended in all healthcare setting
guidelines as the first-line analgesic for both adults and children
experiencing mild to moderate pain (NICE 2016). Paracetamol
is currently available in most countries in healthcare settings and
can be accessed without prescription (WHO 2012).
The recommended dosage for paediatric patients under 18 years
old is generally 10 to 15 mg/kg (BNF 2016; FDA 2017; TGA
2017). For adolescents (12 years and older) recommended doses
are 500 to 1000 mg oral tablet or liquid formula (via rectum
3Paracetamol (acetaminophen) for chronic non-cancer pain in children and adolescents (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
if necessary), at a frequency of every four to six hours, with a
maximum of 4 g over 24 hours. For children under 12 years, oral
and rectal doses are recommended as follows at the same frequency:
500 mg (10 to 12 years), 375 mg (8 to 10 years), 250 mg (6 to
8 years), 240 mg (4 to 6 years), 180 mg (2 to 4 years), 120 mg
(6 to 24 months), and 60 mg (3 to 6 months). Paracetamol is the
only recommended analgesic for children under 3 months of age
(WHO 2012).
Paracetamol has been proven to be safe in appropriate and con-
trolled dosages (Forrest 1982). However, adverse effects of parac-
etamol in the paediatric population can include hepatic or renal
failurewith overuse or overdose (Zyoud 2015).Other less common
side effects include: malaise; toxic epidermal necrolysis skin re-
actions (including Stevens-Johnson syndrome), acute generalised
exanthematous pustulosis; blood disorders including neutropenia,
leucopenia, thrombocytopenia; and upon infusion, hypotension,
flushing, and tachycardia (BNF 2016; Forrest 1982 ).
How the intervention might work
Although paracetamol has been widely used in medical practice,
its mechanism of action remains uncertain (Graham 2013). The
main proposed mechanism is the inhibition of cyclooxygenase
(COX) enzymes through metabolism by the peroxidase function
of these isoenzymes. This process results in inhibition of phenoxyl
radical formation from a critical tyrosine residue important for the
cyclooxygenase activity of COX-1 and COX-2 and prostaglandin
synthesis (Graham 2013; Jozwiak-Bebenista 2014). Paracetamol
is a preferential inhibitor of COX-2 due to its gastrointestinal
tolerance and poor inhibition of platelet activity (Graham 2013;
Hinz 2008; Hinz 2012).
Paracetamol is widely considered to be a safe drug when admin-
istered in appropriate doses (Jozwiak-Bebenista 2014); however,
there is clear evidence that higher doses or prolonged use of parac-
etamol can lead to liver failure (where the paracetamol compounds
are metabolised), cardiovascular events, and even death (Chan
2006; Daly 2008; Forman 2005; Graham 2013; Roberts 2016;
Sheen 2002). Overall, paracetamol is considered to be a safe and
effective analgesic option that is tolerable in the majority of pae-
diatric patients. Using the recommended doses, severe side effects
can be avoided and adequate relief of chronic pain can be achieved
for the infant, child, or adolescent.
Why it is important to do this review
The paediatric population is at risk of inadequate management
of pain (AMA 2013). Some conditions that would be aggressively
treated in adult patients are being managed with insufficient anal-
gesia in younger populations (AMA 2013). Although there have
been repeated calls for best evidence to treat children’s pain, such
as Eccleston 2003, there are no easily available summaries of the
most effective paediatric pain relief.
This review formed part of a Programme Grant addressing the
unmet needs of people with chronic pain, commissioned by the
National Institute for Health Research (NIHR) in the UK. This
topic was identified in June 2015 during consultation with experts
in paediatric pain. Please see Appendix 1 for full details of the
meeting. The standards used to assess evidence in chronic pain
trials have changed substantially in recent years, with particular
attention being paid to trial duration, withdrawals, and statistical
imputation following withdrawal, all of which can substantially
alter estimates of efficacy. The most important change was to en-
courage a move from using average pain scores, or average change
in pain scores, to the number of children who have a large de-
crease in pain (by at least 50%). Pain intensity reduction of 50%
or more has been shown to correlate with improvements in co-
morbid symptoms, function, and quality of life (Moore 2011a).
These standards are set out in the reference guide for pain studies
(AUREF 2012).
O B J E C T I V E S
To assess the analgesic efficacy and adverse events of paracetamol
(acetaminophen) used to treat chronic non-cancer pain in children
and adolescents aged between birth and 17 years, in any setting.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We planned to include randomised controlled trials, with or with-
out blinding, and participant- or observer-reported outcomes.
Full journal publication was required, with the exception of online
clinical trial results, summaries of otherwise unpublished clinical
trials, and abstracts with sufficient data for analysis. We planned to
include studies published in any language. We excluded abstracts
(usually meeting reports) or unpublished data, non-randomised
studies, studies of experimental pain, case reports, and clinical
observations.
Types of participants
We planned to include studies of infants, children, and adoles-
cents, aged from birth to 17 years old, with chronic or recurrent
pain (lasting for three months or longer), arising from genetic con-
ditions, neuropathy, or other conditions. These included but were
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not limited to chronic musculoskeletal pain and chronic abdom-
inal pain.
We excluded studies of perioperative pain, acute pain, cancer pain,
headache, migraine, and pain associated with primary disease or
its treatment.
We planned to include studies of participants with more than
one type of chronic pain, in which case we would analyse results
according to the primary condition.
Types of interventions
We planned to include studies reporting interventions prescribing
paracetamol for the relief of chronic pain by any route, in any dose,
with comparison to a placebo or any active comparator.We did not
consider interventions prescribing paracetamol in combination
with another drug (such as opioids), as this comparison is covered
in the two opioid reviews as part of this suite (Cooper 2017a;
Wiffen 2017a).
Types of outcome measures
In order to be eligible for inclusion in this review, studies had
to report pain assessment, as well as meeting the other selection
criteria.
We planned to include trials measuring pain intensity and pain
relief assessed using validated tools such as numerical rating scale
(NRS), visual analogue scale (VAS), Faces Pain Scale - Revised
(FPS-R), Colour Analogue Scale (CAS), or any other validated
rating scale.
We were particularly interested in Pediatric Initiative onMethods,
Measurement, and Pain Assessment in Clinical Trials (PedIMM-
PACT) definitions for moderate and substantial benefit in chronic
pain studies (PedIMMPACT 2008). These are defined as: at least
30% pain relief over baseline (moderate); at least 50% pain relief
over baseline (substantial); much or very much improved on Pa-
tient Global Impression of Change scale (PGIC) (moderate); very
much improved on PGIC (substantial).
These outcomes differ from those used in most earlier reviews,
concentrating as they do on dichotomous outcomes where pain
responses do not follow a normal (Gaussian) distribution. People
with chronic pain desire high levels of pain relief, ideally more
than 50% pain intensity reduction, and ideally having no worse
than mild pain (Moore 2013a; O’Brien 2010).
We planned to record any reported adverse events. We planned to
report the timing of outcome assessments.
Primary outcomes
1. Participant-reported pain relief of 30% or greater
2. Participant-reported pain relief of 50% or greater
3. PGIC much or very much improved
In the absence of self reported pain, we planned to consider the use
of ’other-reported’ pain, typically by an observer such as a parent,
carer, or healthcare professional (Stinson 2006; von Baeyer 2007).
Secondary outcomes
We identified the following with reference to the PedIMMPACT
recommendations, which suggest core outcome domains andmea-
sures for consideration in paediatric acute and chronic/recurrent
pain clinical trials (PedIMMPACT 2008).
1. Carer Global Impression of Change
2. Requirement for rescue analgesia
3. Sleep duration and quality
4. Acceptability of treatment
5. Physical functioning as defined by validated scales
6. Quality of life as defined by validated scales
7. Any adverse events
8. Withdrawals due to adverse events
9. Any serious adverse event. Serious adverse events typically
include any untoward medical occurrence or effect that at any
dose results in death, is life-threatening, requires hospitalisation
or prolongation of existing hospitalisation, results in persistent or
significant disability or incapacity, is a congenital anomaly or
birth defect, is an ’important medical event’ that may jeopardise
the patient, or may require an intervention to prevent one of the
above characteristics or consequences.
Search methods for identification of studies
We developed the search strategy based on previous strategies
used by the Cochrane Pain, Palliative and Supportive Care Review
Group and carried out the searches.
Electronic searches
We searched the following databases:
• Cochrane Central Register of Controlled Trials
(CENTRAL) (via Cochrane Register of Studies Online),
searched 6 September 2016;
• MEDLINE (via Ovid) (1946 to September week 2 2016);
• Embase (via Ovid) (1974 to 2016 week 38).
We used medical subject headings (MeSH) or equivalent and text
word terms. We restricted our search to randomised controlled
trials and clinical trials. Therewere no language or date restrictions.
The focus of the key words in our search terms was on chronic
pain andparacetamol.We tailored searches to individual databases.
The search strategy for MEDLINE is in Appendix 3, Embase in
Appendix 4, and CENTRAL in Appendix 5.
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Searching other resources
We searched ClinicalTrials.gov (www.clinicaltrials.gov) and the
World Health Organization International Clinical Trials Registry
Platform (WHO ICTRP) (apps.who.int/trialsearch/) for ongoing
trials up to June 2017. In addition, we checked reference lists of
reviews and retrieved articles for additional studies, and performed
citation searches on key articles. We planned to contact experts in
the field for unpublished and ongoing trials, however this was not
necessary. We planned to contact study authors where necessary
for additional information.
Data collection and analysis
We planned to perform separate analyses according to particular
chronic pain conditions. We planned to combine different chronic
pain conditions in analyses for exploratory purposes only.
Selection of studies
Two review authors independently determined study eligibility by
reading the abstract of each study identified by the search. Review
authors independently eliminated studies that clearly did not sat-
isfy inclusion criteria, and obtained full copies of the remaining
studies. Two review authors independently read these studies to
select those that met the inclusion criteria, a third review author
adjudicating in the event of disagreement. We did not anonymise
the studies in any way before assessment. We included a PRISMA
flow chart to illustrate the results of the search and the process of
screening and selecting studies for inclusion in the review (Moher
2009), as recommended in section 11.2.1 of the Cochrane Hand-
book for Systematic Reviews of Interventions (Higgins 2011). We
planned to include studies in the review irrespective of whether
measured outcome data were reported in a ‘usable’ way.
Data extraction and management
Weplanned to obtain full copies of the studies with two review au-
thors independently carrying out data extraction.Where available,
we would have extracted information about the pain condition,
number of participants treated, drug and dosing regimen, study
design (placebo or active control), study duration and follow-up,
analgesic outcome measures and results, withdrawals, and adverse
events (participants experiencing any adverse event or serious ad-
verse event). We planned to collate multiple reports of the same
study, so that each study rather than each report was the unit of
interest in the review. We planned to collect characteristics of the
included studies in sufficient detail to populate a Characteristics
of included studies table.
We planned to use a template data extraction form and checked for
agreement before entry into Cochrane’s statistical software Review
Manager 5 (RevMan 2014).
If a study hadmore than two intervention arms,we planned to only
include the intervention groups and control groups that met the
eligibility criteria. If multi-arm studies were included, we planned
to analyse multiple intervention groups in an appropriate way
that avoided arbitrary omission of relevant groups and double-
counting of participants.
Assessment of risk of bias in included studies
We planned for two review authors to independently assess risk
of bias for each study, using the criteria outlined in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
We planned to complete a ’Risk of bias’ table for each included
study using the Cochrane ’Risk of bias’ tool in Review Manager 5
(RevMan 2014).
We planned to assess the following for each study. We would have
resolved any disagreements by discussion between review authors
or when necessary by consulting a third review author.
1. Random sequence generation (checking for possible
selection bias). We planned to assess the method used to generate
the allocation sequence as: low risk of bias (i.e. any truly random
process, e.g. random number table; computer random number
generator); or unclear risk of bias (when the method used to
generate the sequence was not clearly stated). We excluded
studies that used a non-random process and were therefore at
high risk of bias (e.g. odd or even date of birth; hospital or clinic
record number).
2. Allocation concealment (checking for possible selection
bias). The method used to conceal allocation to interventions
prior to assignment determines whether intervention allocation
could have been foreseen in advance of, or during, recruitment,
or changed after assignment. We planned to assess the methods
as: low risk of bias (e.g. telephone or central randomisation;
consecutively numbered, sealed, opaque envelopes); or unclear
risk of bias (when the method was not clearly stated). We
excluded studies that did not conceal allocation and were
therefore at a high risk of bias (e.g. open list).
3. Blinding of participants and personnel (checking for
possible performance bias). We planned to assess any methods
used to blind the participants and personnel from knowledge of
which intervention a participant received. We planned to assess
the methods as: low risk of bias (study states that the participants
and personnel involved were blinded to treatment groups);
unclear risk of bias (study does not state whether or not
participants and personnel were blinded to treatment groups); or
high risk of bias (participants or personnel were not blinded) (as
stated in Types of studies, we included trials with or without
blinding, and participant- or observer-reported outcomes).
4. Blinding of outcome assessment (checking for possible
detection bias). We planned to assess any methods used to blind
the outcome assessors from knowledge of which intervention a
participant received. We planned to assess the methods as: low
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risk of bias (e.g. study states that it was single-blinded and
describes the method used to achieve blinding of the outcome
assessor); unclear risk of bias (study states that outcome assessors
were blinded but does not provide an adequate description of
how this was achieved); or high risk of bias (outcome assessors
were not blinded) (as stated in Types of studies, we included
trials with or without blinding, and participant- or observer-
reported outcomes).
5. Incomplete outcome data (checking for possible attrition
bias due to the amount, nature, and handling of incomplete
outcome data). We planned to assess the methods used to deal
with incomplete data as: low risk of bias (i.e. less than 10% of
participants did not complete the study or ’baseline observation
carried forward’ (BOCF) analysis was used, or both); unclear risk
of bias (used ’last observation carried forward’ (LOCF) analysis);
or high risk of bias (used ’completer’ analysis).
6. Selective reporting (checking for possible reporting bias).
We planned to assess the methods used to report the outcomes of
the study as: low risk of bias (if all planned outcomes in the
protocol or methods were reported in the results); unclear risk of
bias (if there was not a clear distinction between planned
outcomes and reported outcomes); high risk of bias (if some
planned outcomes from the protocol or methods were clearly not
reported in the results).
7. Size of study (checking for possible biases confounded by
small size). We planned to assess studies as being at low risk of
bias (200 participants or more per treatment arm); unclear risk
of bias (50 to 199 participants per treatment arm); or high risk of
bias (fewer than 50 participants per treatment arm).
8. Other bias. We planned to assess studies for any additional
sources of bias as low, unclear, or high risk of bias, and provide
rationale.
Measures of treatment effect
Where dichotomous data were available, we planned to calculate
a risk ratio (RR) with 95% confidence interval (CI) and meta-
analyse the data as appropriate. We planned to calculate num-
ber needed to treat for an additional beneficial outcome (NNTB)
where appropriate (McQuay 1998); for unwanted effects the
NNTB becomes the number needed to treat for an additional
harmful outcome (NNTH) and is calculated in the same manner.
Where continuous data were reported, we planned to use appro-
priate methods to combine these data in the meta-analysis.
Unit of analysis issues
We planned to accept randomisation to the individual participant
only. We planned to split the control treatment arm between ac-
tive treatment arms in a single study if the active treatment arms
were not combined for analysis. We only accepted studies with
minimum 10 participants per treatment arm.
Dealing with missing data
We planned to use intention-to-treat analysis where the inten-
tion-to-treat population consisted of participants who were ran-
domised, took at least one dose of the assigned study medication,
and provided at least one postbaseline assessment. We would have
assigned missing participants zero improvement wherever possi-
ble.
Assessment of heterogeneity
We planned to identify and measure heterogeneity as recom-
mended in Chapter 9 of the Cochrane Handbook for Systematic
Reviews of Interventions (Higgins 2011). We planned to deal with
clinical heterogeneity by combining studies that examined similar
conditions. We planned to undertake and present a meta-analysis
only if we judged participants, interventions, comparisons, and
outcomes to be sufficiently similar to ensure a clinically meaning-
ful answer. We planned to assess statistical heterogeneity visually
and by using the I² statistic (L’Abbé 1987). When I² was greater
than 50%, we planned to consider the possible reasons.
Assessment of reporting biases
We planned to assess the risk of reporting bias, as recommended
in chapter 8 of the Cochrane Handbook for Systematic Reviews of
Interventions (Higgins 2011).
The aim of this reviewwas to use dichotomous outcomes of known
utility and of value to patients (Hoffman 2010; Moore 2010b;
Moore 2010c; Moore 2010d; Moore 2013a). The review did not
depend on what the authors of the original studies chose to re-
port or not, though clearly difficulties arose in studies failing to
report any dichotomous results. We planned to extract and report
continuous data in a narrative way, which probably reflect efficacy
and utility poorly, and is useful for illustrative purposes only.
We planned to assess publication bias using a method designed to
detect the amount of unpublished data with a null effect required
to make any result clinically irrelevant (usually taken to mean a
number needed to treat (NNT) of 10 or higher) (Moore 2008).
Data synthesis
We planned to use a fixed-effect model for meta-analysis. We
planned to use a random-effects model for meta-analysis if there
was significant clinical heterogeneity and combining studies was
considered to be appropriate. We planned to conduct our analysis
using the primary outcomes of pain and adverse events, and to
calculate the NNTHs for adverse events. We planned to use the
Cochrane software program Review Manager 5 (RevMan 2014).
Quality of the evidence
To analyse data, two review authors independently rated the qual-
ity of each outcome. We used the GRADE approach to assess the
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quality of the body of evidence related to each of the key outcomes,
and planned to report our judgement in a ’Summary of findings’
table per Chapter 12 of the Cochrane Handbook (Appendix 6)
(Higgins 2011).
In addition, there may be circumstances where the overall rating
for a particular outcome would need to be adjusted per GRADE
guidelines (Guyatt 2013a). For example, if there were so few data
that the results were highly susceptible to the random play of
chance, or if studies used LOCF imputation in circumstances
where there were substantial differences in adverse event with-
drawals, one would have no confidence in the result, and would
need to downgrade the quality of the evidence by three levels, to
very low quality. In circumstances where no data were reported
for an outcome, we planned to report the level of evidence as ’no
evidence to support or refute’ (Guyatt 2013b).
’Summary of findings’ table
We planned to include a ’Summary of findings’ table as set out in
the Cochrane Pain, Palliative and Supportive Care ReviewGroup’s
author guide (AUREF 2012), and recommended in section 4.6.6
of the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011). We planned to justify and document all assess-
ments of the quality of the body of evidence.
In an attempt to reliably interpret the findings of this systematic re-
view, we planned to assess the summarised data using the GRADE
guidelines (Appendix 6) to rate the quality of the body of evidence
of each of the key outcomes listed in Types of outcome measures
per Chapter 12 of theCochrane Handbook, as appropriate (Guyatt
2011; Higgins 2011). Utilising the explicit criteria against study
design, risk of bias, imprecision, inconsistency, indirectness, and
magnitude of effect, we planned to summarise the evidence in an
informative, transparent, and succinct ’Summary of findings’ table
or ’Evidence profile’ table (Guyatt 2011).
Subgroup analysis and investigation of heterogeneity
We planned to perform subgroup analyses where a minimum
number of data were available (at least 200 participants per treat-
ment arm). We planned to analyse according to age group; type
of drug; geographical location or country; type of control group;
baseline measures; frequency, dose, and duration of drugs; and
nature of drug.
We planned to investigate whether the results of subgroups were
significantly different by inspecting the overlap of confidence in-
tervals and by performing the test for subgroup differences avail-
able in Review Manager 5.
Sensitivity analysis
We did not plan to carry out any sensitivity analysis because the
evidence base is known to be too small to allow reliable analysis; we
did not plan to pool results from chronic pain of different origins
in the primary analyses. We planned to examine details of dose
escalation schedules in the unlikely circumstance that this could
provide some basis for a sensitivity analysis.
R E S U L T S
Description of studies
Results of the search
A PRISMA flow diagram of the search results is shown in Figure
1.
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Figure 1. Study flow diagram.
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Searches of the three main databases revealed 2979 records of
titles and abstracts, of which 1020 duplicates were removed. Our
searches of ClinicalTrials.gov and the WHO ICTRP yielded no
additional eligible studies.
We screened the remaining 1959 titles and abstracts for eligibility,
finding 1953 to be ineligible.
We read the full texts of the remaining six studies, of which all
six were found to be ineligible and excluded. We identified no
ongoing studies. No studies fulfilled the inclusion criteria or were
eligible to be entered into a quantitative analysis.
Included studies
No studies met our inclusion criteria for this review.
Excluded studies
See Characteristics of excluded studies.
We excluded six studies in this review. Five investigated adult pop-
ulations, and one study was not randomised. (McGuinness 1969).
Risk of bias in included studies
No studies were eligible for inclusion in this review, therefore we
did not perform a ’Risk of bias’ assessment.
Effects of interventions
No studies were eligible for inclusion in this review, therefore we
could not assess the efficacy of paracetamol to treat chronic non-
cancer pain in children and adolescents. We rated the quality of
the evidence as very low. We downgraded the quality of evidence
by three levels due to the lack of data reported for any outcome.
D I S C U S S I O N
Summary of main results
We were unable to find any randomised controlled trials for inclu-
sion in this review, therefore we were unable to comment about
efficacy or harm from the use of paracetamol to treat chronic non-
cancer pain in children and adolescents. Similarly, we could not
comment on our remaining secondary outcomes: Carer Global
Impression of Change; requirement for rescue analgesia; sleep du-
ration and quality; acceptability of treatment; physical function-
ing; and quality of life.
Overall completeness and applicability of
evidence
In adults, the efficacy of paracetamol in chronic pain conditions
is being challenged. Paracetamol alone is no better than placebo
for low back pain (Saragiotto 2016), spinal pain, or osteoarthritis
(Machado 2015), and there is very little evidence of efficacy in
neuropathic pain, despite its widespread use (Wiffen 2016). The
efficacy of paracetamol in acute pain is established in acute post-
operative pain, Moore 2015, and migraine (Derry 2013). Parac-
etamol is generally less effective than non-steroidal anti-inflamma-
tory drugs (Marjoribanks 2015; Moore 2015). Widespread use of
paracetamol combined with new evidence about harm has chal-
lenged the common assumption of safety (Moore 2016; Roberts
2016).
In children, there is little evidence concerning the pain-relieving
effects of paracetamol in neonates (Ohlsson 2016), for acute otitis
media (Sjoukes 2016), or for relief of fever (Wong 2013).
The suite of reviews
This review is part of a suite of reviews on pharmacological in-
terventions for chronic pain and cancer-related pain in children
and adolescents (Appendix 1). Taking a broader view on this suite
of reviews, some pharmacotherapies (investigated in our other re-
views) are likely to provide more data than others. The results of
this reviewwere thus as expected considering that randomised con-
trolled trials in children are known to be limited. The results have
the potential to inform policymaking decisions for funding future
clinical trials into paracetamol treatment of child and adolescent
pain, therefore any results (large or small) are important in order
to capture a snapshot of the current evidence for paracetamol.
Quality of the evidence
No studies were eligible for inclusion in this review. We rated the
quality of the evidence as very low. We downgraded the quality of
evidence by three levels due to the lack of data reported for any
outcome.
We were unable to find any published randomised controlled tri-
als to support or refute the use of paracetamol to treat chronic
non-cancer pain in children and adolescents. We were unable to
examine any adverse effects.
This review shows that there is an absence of evidence from trials
that paracetamol is effective in chronic non-cancer pain in chil-
dren. While it may be the case that this absence of evidence re-
flects the inadequacy of paracetamol for this purpose and that its
use as a monotherapy analgesic is more likely to cause harm than
benefit, the opposite may also pertain, as the data are lacking. It
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is difficult to conduct long-term randomised controlled trials in
children with chronic non-cancer conditions, and few observa-
tional/clinical data have been published.
Potential biases in the review process
We carried out extensive searches of major databases using broad
search criteria, and also searched two large clinical trial registries.
We consider it to be unlikely that we have missed relevant studies.
Agreements and disagreements with other
studies or reviews
We were not able to identify any published systematic reviews on
this topic.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
General
We identified no randomised controlled trials to support or refute
the use of paracetamol to treat chronic non-cancer pain in children
and adolescents.
This is disappointing as children and adolescents have specific
needs for analgesia. Extrapolating from adult data may be possible
but could compromise effectiveness and safety.
Despite the lack of evidence of long-term effectiveness and safety,
clinicians prescribe paracetamol to children and adolescents when
medically necessary, based on extrapolation from adult guidelines,
or when perceived benefits in conjunction with other multimodal-
ities improve a child’s care. Appropriate medical management is
necessary in disease-specific conditions such as for incurable pro-
gressive degenerative conditions of Duchenne muscular dystro-
phy, osteogenesis imperfecta, congenital degenerative spine, and
neurodegenerative conditions such as spasticity/dystonia in mito-
chondrial Leigh’s disease, leukoencephalopathy, and severe cere-
bral palsy.
For children with chronic non-cancer pain
The amount and quality of evidence around the use of paracetamol
for treating chronic non-cancer pain is low. This means that at
present, treatment is based on clinical experience and advice from
respected authorities. We could make no judgement about adverse
events or withdrawals.
For clinicians
The amount and quality of evidence around the use of paracetamol
for treating chronic non-cancer pain is low. This means that at
present, treatment is based on clinical experience and advice from
respected authorities. We could make no judgement about adverse
events or withdrawals.
For policymakers
The amount and quality of evidence around the use of paracetamol
for treating chronic non-cancer pain is low. This means that at
present, treatment is based on clinical experience and advice from
respected authorities. We could make no judgement about adverse
events or withdrawals.
For funders
The amount and quality of evidence around the use of paracetamol
for treating chronic non-cancer pain is low. This means that at
present, treatment is based on clinical experience and advice from
respected authorities. We could make no judgement about adverse
events or withdrawals.
Implications for research
General
The heterogeneous nature of pain in children needs to be recog-
nised and presents challenges in designing research studies.
Overall, there appears to be a gap between what is done in practice
and what is investigated in prospective clinical trials for treating
children’s and adolescents’ pain with paracetamol.
The lack of evidence highlighted in this review implies that there
is a need to fund and support suitable research for the treatment
of chronic non-cancer pain in children and adolescents.
Design
Several methodological issues stand out.
The first is the use of outcomes of value to children with chronic
non-cancer pain. Existing trials are designed more for purposes of
registration and marketing than informing and improving clinical
practice, that is the outcomes are often average pain scores or
statistical differences, and rarely how many individuals achieve
satisfactory pain relief. In the case where pain is initially mild or
moderate, consideration needs to be given to what constitutes a
satisfactory outcome. The situation is somewhat different to that
of strong opioids that are used for moderate to severe cancer pain.
The second issue is the time taken to achieve good pain relief. We
have no information about what constitutes a reasonable time to
11Paracetamol (acetaminophen) for chronic non-cancer pain in children and adolescents (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
achieve a satisfactory result. This may best be approached initially
with a Delphi methodology.
The third issue is design. Studies with a cross-over design often
have significant attrition, therefore parallel-group designs may be
preferable. Alternative concentration-response or dose-response
relationships in individual children could be explored using popu-
lation analysis techniques (Anderson 2015). These have been used
to explore acute pain in both adults and children as well as chronic
pain in adults (Shinoda 2007).
The fourth issue is size. The studies need to be suitably powered
to ensure adequate data after the effect of attrition due to various
causes.Much larger studies of several hundredparticipants ormore
are needed.
There are some other design issues that might be addressed. Most
important might well be a clear decision concerning the gold-
standard treatment comparator.
An alternative approach may be to design large registry studies.
This could provide an opportunity to foster collaboration among
paediatric clinicians and researchers, in order to create an evidence
base.
Measurement (endpoints)
Trials need to consider the additional endpoint of ’no worse than
mild pain’ as well as the standard approaches to pain assessment.
Other
The obvious study design of choice is the prospective randomised
trial, but other pragmatic designs may be worth considering. Stud-
ies could incorporate initial randomisation but a pragmatic de-
sign in order to provide immediately relevant information on ef-
fectiveness and costs. Such designs in pain conditions have been
published (Moore 2010e).
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Ali 2007 Participants: women aged 18 years and over
Intervention: paracetamol combined with caffeine, not paracetamol alone
Berry 1975 Adult population, participants aged 16 to 39 years (mean 26 years)
Cubero 2010 Participants aged 18 years and over
McGuinness 1969 Not randomised
Mueller-Lissner 2005 Participants aged 18 years and over
Valle-Jones 1992 Participants: age range 14 to 76 years, however, mean age was 43 years. Unlikely to gain subunit data for 14
to 17 years
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D A T A A N D A N A L Y S E S
This review has no analyses.
A P P E N D I C E S
Appendix 1. Meeting for NIHR Programme Grant agenda on pain in children
Date
Monday 1st June 2015
Location
International Association of the Study of Pain (IASP) Conference, Seattle, USA
Delegates
AllenFinlay, AnnaErskine, BorisZernikow,ChantalWood,Christopher Eccleston, ElliotKrane,GeorgeChalkaiadis,Gustaf Ljungman,
Jacqui Clinch, Jeffrey Gold, Julia Wager, Marie-Claude Gregoire, Miranda van Tilburg, Navil Sethna, Neil Schechter, Phil Wiffen,
Richard Howard, Susie Lord.
Purpose
National Institute for Health Research (NIHR) (UK) Programme Grant - Addressing the unmet need of chronic pain: providing the
evidence for treatments of pain.
Proposal
Nine reviews in pharmacological interventions for chronic pain in children and adolescents: Children (5 new, 1 update, 1 overview, and
2 rapid) self-management of chronic pain is prioritised by the planned NICE guideline. Pain management (young people and adults)
with a focus on initial assessment and management of persistent pain in young people and adults.
We propose titles in paracetamol, ibuprofen, diclofenac, other NSAIDs, and codeine, an overview review on pain in the community,
2 rapid reviews on the pharmacotherapy of chronic pain, and cancer pain, and an update of psychological treatments for chronic pain.
Key outcomes
The final titles: (1) opioids for cancer-related pain (Wiffen 2017a), (2) opioids for chronic non-cancer pain (Cooper 2017a), (3)
antiepileptic drugs for chronic non-cancer pain (Wiffen 2017b), (4) antidepressants for chronic non-cancer pain (Cooper 2017b), (5)
non-steroidal anti-inflammatory drugs (NSAIDs) for chronic non-cancer pain (Eccleston 2017), (6) non-steroidal anti-inflammatory
drugs (NSAIDs) for cancer-related pain (Cooper 2017c), (7) paracetamol for chronic non-cancer pain (Cooper 2017d - this review).
PICO
Patients : children, aged 3 to 12, chronic pain defined as pain persisting for 3 months (NB: now changed to: birth to 17 years to include
infants, children and adolescents).
Interventions : by drug class including antiepileptic drugs, antidepressants, opioids, NSAIDs, paracetamol.
Comparisons : maintain a separation of cancer and non-cancer, exclude headache, in comparison with placebo and or active control.
Outcomes : we will adopt the IMMPACT criteria.
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Appendix 2. Methodological considerations for chronic pain
There have been several recent changes in how the efficacy of conventional and unconventional treatments is assessed in chronic painful
conditions. The outcomes are now better defined, particularly with new criteria for what constitutes moderate or substantial benefit
(Dworkin 2008); older trials may only report participants with ’any improvement’. Newer trials tend to be larger, avoiding problems
from the random play of chance. Newer trials also tend to be of longer duration, up to 12 weeks, and longer trials provide a more
rigorous and valid assessment of efficacy in chronic conditions. New standards have evolved for assessing efficacy in neuropathic pain,
and we are now applying stricter criteria for the inclusion of trials and assessment of outcomes, and are more aware of problems that
may affect our overall assessment. In this new review we summarise some of the recent insights that must be considered.
1. Pain results tend to have a U-shaped distribution rather than a bell-shaped distribution. This is true in acute pain (Moore 2011a;
Moore 2011b), back pain (Moore 2010d), and arthritis (Moore 2010c), as well as in fibromyalgia (Straube 2010); in all cases average
results usually describe the experience of almost no one in the trial. Data expressed as averages are potentially misleading, unless they
can be proven to be suitable.
2. As a consequence, we have to depend on dichotomous results (the individual either has or does not have the outcome) usually
from pain changes or patient global assessments. The Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials
(IMMPACT) group has helped with their definitions of minimal, moderate, and substantial improvement (Dworkin 2008). In
arthritis, trials of less than 12 weeks’ duration, and especially those shorter than eight weeks, overestimate the effect of treatment
(Moore 2010c); the effect is particularly strong for less effective analgesics, and this may also be relevant in neuropathic-type pain.
3. The proportion of patients with at least moderate benefit can be small, even with an effective medicine, falling from 60% with
an effective medicine in arthritis to 30% in fibromyalgia (Moore 2009; Moore 2010c; Moore 2013b; Moore 2014b; Straube 2008;
Sultan 2008). A Cochrane review of pregabalin in neuropathic pain and fibromyalgia demonstrated different response rates for
different types of chronic pain (higher in diabetic neuropathy and postherpetic neuralgia and lower in central pain and fibromyalgia)
(Moore 2009). This indicates that different neuropathic pain conditions should be treated separately from one another, and that
pooling should not be done unless there are good grounds for doing so.
4. Individual patient analyses indicate that patients who get good pain relief (moderate or better) have major benefits in many
other outcomes, affecting quality of life in a significant way (Moore 2010b; Moore 2014a).
5. Imputation methods such as last observation carried forward (LOCF), used when participants withdraw from clinical trials, can
overstate drug efficacy, especially when adverse event withdrawals with drug are greater than those with placebo (Moore 2012).
Appendix 3. MEDLINE search strategy (via Ovid)
1. exp Child/ (1704648)
2. exp Adolescent/ (1771784)
3. (child* or boy* or girl* or adolescen* or teen* or toddler* or preschooler* or pre-schooler*).mp. (2964105)
4. 1 or 2 or 3 (2964105)
5. Acetaminophen/ (15579)
6. (acetaminophen or paracetamol or Calpol or Panadol or Tylenol).mp. (21431)
7. 5 or 6 (21431)
8. exp Pain/ (337664)
9. 4 and 7 and 8 (1222)
10. randomized controlled trial.pt. (428796)
11. controlled clinical trial.pt. (91589)
12. randomized.ab. (324920)
13. placebo.ab. (164048)
14. drug therapy.fs. (1900854)
15. randomly.ab. (228088)
16. trial.ab. (338664)
17. groups.ab. (1434250)
18. 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 (3621582)
19. 9 and 18 (1091)
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Appendix 4. Embase search strategy (via Ovid)
1. exp Child/ (2355146)
2. exp Adolescent/ (1376095)
3. (child* or boy* or girl* or adolescen* or teen* or toddler* or preschooler* or pre-schooler*).mp. (3076161)
4. 1 or 2 or 3 (3533100)
5. Paracetamol/ (73297)
6. (acetaminophen or paracetamol or Calpol or Panadol or Tylenol).mp. (78105)
7. 5 or 6 (78105)
8. exp Pain/ (1005936)
9. 4 and 7 and 8 (5286)
10. crossover-procedure/ (48531)
11. double-blind procedure/ (133820)
12. randomized controlled trial/ (418791)
13. (random* or factorial* or crossover* or cross over* or cross-over* or placebo* or (doubl* adj blind*) or assign* or allocat*).tw.
(1496531)
14. (random* or factorial* or crossover* or cross over* or cross-over* or placebo* or (doubl* adj blind*) or assign* or allocat*).tw.
(1582964)
15. 9 and 14 (1208)
Appendix 5. CENTRAL search strategy (via CRSO)
1. MESH DESCRIPTOR Child EXPLODE ALL TREES (203)
2. MESH DESCRIPTOR Adolescent (86514)
3. (child* or boy* or girl* or adolescen* or teen* or toddler* or preschooler* or pre-schooler*):TI,AB,KY (152721)
4. #1 OR #2 OR #3 (152721)
5. MESH DESCRIPTOR Acetaminophen (1893)
6. (acetaminophen or paracetamol or Calpol or Panadol or Tylenol):TI,AB,KY (5698)
7. #5 OR #6 (5698)
8. MESH DESCRIPTOR Pain EXPLODE ALL TREES (32731)
9. #4 AND #7 AND #8 (680)
Appendix 6. GRADE guidelines
Some advantages of utilising the GRADE process are (Guyatt 2008):
• transparent process of moving from evidence to recommendations;
• clear separation between quality of evidence and strength of recommendations;
• explicit, comprehensive criteria for downgrading and upgrading quality of evidence ratings; and
• clear, pragmatic interpretation of strong versus weak recommendations for clinicians, patients, and policymakers.
The GRADE system uses the following criteria for assigning grades of evidence:
• high: we are very confident that the true effect lies close to that of the estimate of the effect;
• moderate: we are moderately confident in the effect estimate; the true effect is likely to be close the estimate of effect, but there is
a possibility that it is substantially different;
• low: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect;
and
• very low: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the
estimate of effect.
We will decrease the grade if there is:
• serious (-1) or very serious (-2) limitation to study quality;
• important inconsistency (-1);
• some (-1) or major (-2) uncertainty about directness;
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• imprecise or sparse data (-1); or
• high probability of reporting bias (-1).
We will increase the grade if there is:
• strong evidence of association - significant relative risk of > 2 (< 0.5) based on consistent evidence from two or more
observational studies, with no plausible confounders (+1);
• very strong evidence of association - significant relative risk of > 5 (< 0.2) based on direct evidence with no major threats to
validity (+2);
• evidence of a dose response gradient (+1); or
• all plausible confounders would have reduced the effect (+1).
WH A T ’ S N E W
Last assessed as up-to-date: 6 September 2016.
Date Event Description
14 August 2017 Amended References for some reviews from the suite amended to reflect correct publication Issue
C O N T R I B U T I O N S O F A U T H O R S
TC and CE registered the title.
TC, Phil Wiffen, and CE wrote the template protocol for the suite of children’s reviews, of which this review is a part.
All authors contributed to writing the protocol and all authors agreed on the final version.
TC and EF were responsible for data extraction and analysis.
All authors were responsible for the writing of the Discussion for the full review.
All authors will be responsible for the completion of updates.
D E C L A R A T I O N S O F I N T E R E S T
CE: none known.
TC: none known.
BA: none known; BA is a specialist anaesthetist and intensive care physician and manages the perioperative care of children requiring
surgery and those critically ill requiring intensive care.
EF: none known.
NW: none known; NW is a specialist paediatric pain clinician and treats patients with chronic pain.
DGW: none known; DGW is a consultant in paediatric anaesthesia and pain medicine and treats children with acute and chronic pain.
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S O U R C E S O F S U P P O R T
Internal sources
• No sources of support supplied
External sources
• National Institute for Health Research (NIHR), UK.
NIHR Programme Grant, Award Reference Number: 13/89/29 (Addressing the unmet need of chronic pain: providing the evidence
for treatments of pain)
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We made minor changes to the wording in the Background section.
We did not consider studies with fewer than 10 participants per treatment arm for inclusion in this review, as is standard practice for
this group.
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